A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical trial NCT06769698 · RECRUITING

Trial details

NCT number: NCT06769698
Sponsor: Regeneron Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma (HNSCC)

Start date: 2026-04-14
Primary completion: 2028-06-04
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.